Trial · NCT04975997
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997, Phase 3, Active not recruiting, Celgene
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM). Trials, record NCT04975997. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04975997
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT number
- NCT04975997
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 939 participants, actual
- Lead sponsor
- Celgene
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone, Daratumumab, Bortezomib, Iberdomide, Iberdomide, Iberdomide, Dexamethasone, Daratumumab
- First posted
- 2021-07-26
- Last updated
- 2026-04-03
- Other registries' IDs
- eudract:2020-000431-49
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) | Up to approximately 5 years | To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of progression free survival (PFS). |
| Primary | Minimal Residual Disease (MRD) negative Complete Response (CR) at any time | Up to approximately 5 years | To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of minimal residual disease (MRD) negative complete response (CR) at any time. |
| Secondary | Overall Survival (OS) | Up to approximately 5 years | To evaluate clinical efficacy in terms of overall survival (OS) in participants with relapsed or refractory multiple myeloma (RRMM) treated with iberdomide, daratumumab, and dexamethasone (IberDd) compared to daratumumab, bortezomib, and dexamethasone (DVd). |
| Secondary | Sustainability of Minimal Residual Disease (MRD) negativity | Up to approximately 5 years | To evaluate the sustainability of minimal residual disease (MRD) negativity. |
| Secondary | Overall Response Rate (ORR) | Up to approximately 5 years | Calculated as percentage of participants who achieve best response of partial response (PR) or better according to the IMWG Uniform Response Criteria for multiple myeloma. |
| Secondary | Time to response (TTR) | Up to approximately 5 years | Time from randomization to the first documentation of response (PR or better). |
| Secondary | Duration of Response (DoR) | Up to approximately 5 years | Time from the first documentation of response (PR or better) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. |
| Secondary | Time to Progression (TTP) | Up to approximately 5 years | The time from randomization to the first documented disease progression. |
| Secondary | Time to Next Treatment (TTNT) | Up to approximately 5 years | Time from randomization to the start of the next antimyeloma treatment. |
| Secondary | Progression-free Survival 2 (PFS2) | Up to approximately 5 years | Time from randomization to progression on the next anti-myeloma treatment or death due to any cause, whichever occurs first. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04975997
GET https://conductscience.org/api/trials/v1/NCT04975997/registered